Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2023 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur...
July 26, 2023 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
July 25, 2023 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grant to New Chief Scientific Officer

CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s...
July 24, 2023 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the...
June 14, 2023 22:06 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of...
June 14, 2023 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of...
June 09, 2023 03:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients...
June 06, 2023 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June...
May 18, 2023 16:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s...
May 16, 2023 16:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive...